Psilox AB Competitors

We are Compass, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. We believe people living with mental health conditions deserve the possibility of a better future. Our initial focus is advancing COMP360, a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability, with infrequent dosing. We’re driven by our purpose of unlocking pathways to be—opening futures filled with possibility. Together, we’re on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery. Every journey needs a Compass.

MindMed is now Definium Therapeutics, a rebrand that reflects our commitment to forging a new era of psychiatry by applying precision to psychedelic medicine. Follow our new page at the link below!

Medincell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives. #BetterMedicineForAll #ImpactHealth #GlobalHealth #ControlledRelease #CreativeThinking #InnovationForward #Science